Thus, our model provides a mechanistic explanation for the clinical observation that KEAP1 mutant NSCLC tumours respond poorly to G12Ci drugs, and argues that alternative treatment strategies would be more appropriate for patients who present with KEAP1 or NFE2L2 mutant NSCLC tumours. The gene discussed is KEAP1; the disease is neoplasm.